{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:13:04Z","timestamp":1792624384424,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematopathol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple myeloma (MM) is a malignant neoplasm of clonal plasma cells, typically associated with the production of a monoclonal protein. In 1\u20133% of cases, MM presents without measurable monoclonal protein (M protein) in the serum or urine and normal serum-free light chains; these cases are referred to as non-secretory MM (NSMM). This definition has changed over time according to the sensitivity of laboratory methods for detecting paraproteins. NSMM has been previously reported to have a less aggressive presentation and clinical course compared to secretory MM; however, the literature is conflicting. Recent studies have indicated that NSMM may exhibit different responses to therapy and outcomes, emphasizing the need for a tailored approach. This review consolidates the current understanding of NSMM and underscores the importance of advanced diagnostic techniques in improving patient management and outcomes.\n<\/jats:p>","DOI":"10.1007\/s12308-025-00652-8","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T02:34:02Z","timestamp":1754447642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Where are the immunoglobulins? A review of non-secretory multiple myeloma"],"prefix":"10.1007","volume":"18","author":[{"given":"Marcello Pecoraro","family":"Toscano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8127-7663","authenticated-orcid":false,"given":"Megan O.","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"12","key":"652_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"3","key":"652_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"652_CR3","doi-asserted-by":"publisher","first-page":"7583","DOI":"10.2147\/OTT.S122241","volume":"9","author":"MM Dupuis","year":"2016","unstructured":"Dupuis MM, Tuchman SA (2016) Non-secretory multiple myeloma: from biology to clinical management. OncoTargets Ther 9:7583\u20137590. https:\/\/doi.org\/10.2147\/OTT.S122241","journal-title":"OncoTargets Ther"},{"issue":"2","key":"652_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/leu.2008.307","volume":"23","author":"A Dispenzieri","year":"2009","unstructured":"Dispenzieri A, Kyle R, Merlini G et al (2009) International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23(2):215\u2013224. https:\/\/doi.org\/10.1038\/leu.2008.307","journal-title":"Leukemia"},{"issue":"8","key":"652_CR5","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"issue":"1","key":"652_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/ejh.12478","volume":"95","author":"SS Chawla","year":"2015","unstructured":"Chawla SS, Kumar SK, Dispenzieri A et al (2015) Clinical course and prognosis of non-secretory multiple myeloma. Eur J Haematol 95(1):57\u201364. https:\/\/doi.org\/10.1111\/ejh.12478","journal-title":"Eur J Haematol"},{"issue":"5","key":"652_CR7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/ejh.13351","volume":"104","author":"G W\u00e5linder","year":"2020","unstructured":"W\u00e5linder G, Samuelsson J, N\u00e4sman P et al (2020) Outcome and characteristics of non-measurable myeloma: a cohort study with population-based data from the Swedish Myeloma Registry. Eur J Haematol 104(5):376\u2013382. https:\/\/doi.org\/10.1111\/ejh.13351","journal-title":"Eur J Haematol"},{"issue":"5","key":"652_CR8","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121(5):749\u2013757","journal-title":"Br J Haematol"},{"key":"652_CR9","unstructured":"Lonial S, Kaufman JL (2013) Non-secretory myeloma: a clinician\u2019s guide. Oncol Williston Park N 27(9):924\u2013928, 930"},{"issue":"6","key":"652_CR10","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00277-020-03984-w","volume":"99","author":"M Migkou","year":"2020","unstructured":"Migkou M, Avivi I, Gavriatopoulou M et al (2020) Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. Ann Hematol 99(6):1251\u20131255. https:\/\/doi.org\/10.1007\/s00277-020-03984-w","journal-title":"Ann Hematol"},{"issue":"6","key":"652_CR11","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/s0889-8588(05)70125-8","volume":"13","author":"J Blad\u00e9","year":"1999","unstructured":"Blad\u00e9 J, Kyle RA (1999) Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 13(6):1259\u20131272. https:\/\/doi.org\/10.1016\/s0889-8588(05)70125-8","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"652_CR12","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1182\/blood.v97.9.2900","volume":"97","author":"M Drayson","year":"2001","unstructured":"Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97(9):2900\u20132902. https:\/\/doi.org\/10.1182\/blood.v97.9.2900","journal-title":"Blood"},{"issue":"6","key":"652_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMc1206740","volume":"367","author":"D Larson","year":"2012","unstructured":"Larson D, Kyle RA, Rajkumar SV (2012) Prevalence and monitoring of oligosecretory myeloma. N Engl J Med 367(6):580\u2013581. https:\/\/doi.org\/10.1056\/NEJMc1206740","journal-title":"N Engl J Med"},{"issue":"5","key":"652_CR14","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1373\/clinchem.2004.046870","volume":"51","author":"JA Katzmann","year":"2005","unstructured":"Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA (2005) Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 51(5):878\u2013881. https:\/\/doi.org\/10.1373\/clinchem.2004.046870","journal-title":"Clin Chem"},{"issue":"9","key":"652_CR15","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467\u20131473. https:\/\/doi.org\/10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"issue":"2","key":"652_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/bjh.14753","volume":"178","author":"JLJ Heaney","year":"2017","unstructured":"Heaney JLJ, Campbell JP, Griffin AE et al (2017) Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. Br J Haematol 178(2):220\u2013230. https:\/\/doi.org\/10.1111\/bjh.14753","journal-title":"Br J Haematol"},{"issue":"3","key":"652_CR17","first-page":"428","volume":"25","author":"JL Preud\u2019Homme","year":"1976","unstructured":"Preud\u2019Homme JL, Hurez D, Danon F, Brouet JC, Seligmann M (1976) Intracytoplasmic and surface-bound immunoglobulins in \u201cnonsecretory\u201d and Bence-Jones myeloma. Clin Exp Immunol 25(3):428\u2013436","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"652_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/ajcp\/58.6.618","volume":"58","author":"HA Azar","year":"1972","unstructured":"Azar HA, Zaino EC, Pham TD, Yannopoulos K (1972) \u201cNonsecretory\u201d plasma cell myeloma: observations on seven cases with electron microscopic studies. Am J Clin Pathol 58(6):618\u2013629. https:\/\/doi.org\/10.1093\/ajcp\/58.6.618","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"652_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1365-2141.1979.tb03788.x","volume":"43","author":"MV Joyner","year":"1979","unstructured":"Joyner MV, Cassuto JP, Dujardin P et al (1979) Non-excretory multiple myeloma. Br J Haematol 43(4):559\u2013566. https:\/\/doi.org\/10.1111\/j.1365-2141.1979.tb03788.x","journal-title":"Br J Haematol"},{"issue":"3","key":"652_CR20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1189\/jlb.0803382","volume":"76","author":"C Decourt","year":"2004","unstructured":"Decourt C, Galea HR, Sirac C, Cogn\u00e9 M (2004) Immunologic basis for the rare occurrence of true nonsecretory plasma cell dyscrasias. J Leukoc Biol 76(3):528\u2013536. https:\/\/doi.org\/10.1189\/jlb.0803382","journal-title":"J Leukoc Biol"},{"issue":"3","key":"652_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/bf00996654","volume":"36","author":"S Weiss","year":"1978","unstructured":"Weiss S, Lewinski UH, Pick AJ, Gafter U, Djaldetti M (1978) Ultrastructural features of the plasma cells in\u202f?non-secretory? myeloma. Blut 36(3):149\u2013157. https:\/\/doi.org\/10.1007\/bf00996654","journal-title":"Blut"},{"issue":"3","key":"652_CR22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1182\/blood-2004-02-0477","volume":"104","author":"D Coriu","year":"2004","unstructured":"Coriu D, Weaver K, Schell M et al (2004) A molecular basis for nonsecretory myeloma. Blood 104(3):829\u2013831. https:\/\/doi.org\/10.1182\/blood-2004-02-0477","journal-title":"Blood"},{"issue":"20","key":"652_CR23","doi-asserted-by":"publisher","first-page":"8135","DOI":"10.1073\/pnas.87.20.8135","volume":"87","author":"JL Dul","year":"1990","unstructured":"Dul JL, Argon Y (1990) A single amino acid substitution in the variable region of the light chain specifically blocks immunoglobulin secretion. Proc Natl Acad Sci U S A 87(20):8135\u20138139. https:\/\/doi.org\/10.1073\/pnas.87.20.8135","journal-title":"Proc Natl Acad Sci U S A"},{"key":"652_CR24","doi-asserted-by":"publisher","unstructured":"Avet-Loiseau H, Garand R, Lod\u00e9 L, Harousseau JL, Bataille R, Intergroupe Francophone du My\u00e9lome (2003) Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 101(4):1570\u20131571. https:\/\/doi.org\/10.1182\/blood-2002-08-2436","DOI":"10.1182\/blood-2002-08-2436"},{"key":"652_CR25","doi-asserted-by":"publisher","unstructured":"Leung N, Bridoux F, Hutchison CA, et al (2012) Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 120(22):4292\u20134295. https:\/\/doi.org\/10.1182\/blood-2012-07-445304","DOI":"10.1182\/blood-2012-07-445304"},{"key":"652_CR26","doi-asserted-by":"publisher","unstructured":"Galea HR, Denizot Y, Cogn\u00e9 M (2002) Light chain myeloma plasma cells induce a strong cell-mediated immune response mainly directed against the monoclonal light chain determinants in a murine experimental model. Cancer Immunol Immunother CII 51(4):229\u2013234. https:\/\/doi.org\/10.1007\/s00262-002-0274-6","DOI":"10.1007\/s00262-002-0274-6"},{"issue":"5","key":"652_CR27","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/bloodadvances.2018019851","volume":"3","author":"XQ Qin","year":"2019","unstructured":"Smith DB, Harris M, Gowland E, Chang J, Scarffe JH (1986) Non\u2010secretory multiple myeloma: a report of 13 cases with a review of the literature. Hematol Oncol 4:(4):307\u2013313. https:\/\/doi.org\/10.1002\/hon.2900040407","journal-title":"Blood Adv"},{"issue":"1","key":"652_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clml.2019.09.624","volume":"20","author":"B Nandakumar","year":"2020","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21\u201333. https:\/\/doi.org\/10.4065\/78.1.21","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"652_CR29","doi-asserted-by":"publisher","unstructured":"Qin XQ, An G, Li ZJ, et al (2019) Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study. Blood Adv 3(5):751\u2013760. https:\/\/doi.org\/10.1182\/bloodadvances.2018019851","DOI":"10.1182\/bloodadvances.2018019851"},{"key":"652_CR30","doi-asserted-by":"publisher","unstructured":"Nandakumar B, Kumar SK, Dispenzieri A, et al (2020) Cytogenetic features and clinical outcomes of patients with non-secretory multiple myeloma in the era of novel agent induction therapy. Clin Lymphoma Myeloma Leuk 20(1):53\u201356. https:\/\/doi.org\/10.1016\/j.clml.2019.09.624","DOI":"10.1016\/j.clml.2019.09.624"},{"key":"652_CR31","doi-asserted-by":"crossref","unstructured":"Sun H, Liu A, Liu L, et al (2023) Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China. BMC Cancer 23(1):930 doi:10.1186\/s12885-023-11223-4","DOI":"10.1186\/s12885-023-11223-4"}],"container-title":["Journal of Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-025-00652-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12308-025-00652-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-025-00652-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T20:48:57Z","timestamp":1757364537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12308-025-00652-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1007\/s12308-025-00652-8","relation":{},"ISSN":["1868-9256","1865-5785"],"issn-type":[{"value":"1868-9256","type":"print"},{"value":"1865-5785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was not supported by any funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflict interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict interests"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, informed consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"For this type of study, consent for publication is not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"39"}}